Investment Thesis

Gilead Sciences, Inc. is a BUY at current prices. The market currently underappreciates Gilead’s robust pipeline and its potential for sustained revenue growth, particularly in HIV and oncology treatments. With strong fundamentals and a strategic focus on unmet medical needs, Gilead is poised to capitalize on expanding market opportunities, suggesting that the stock is undervalued relative to its growth trajectory.

Competitive Moat

characterized by its intangible assets, particularly its strong portfolio of patented drugs and established brand reputation in antiviral treatments. The company's extensive R&D capabilities and regulatory expertise create high barriers for new entrants, and its established market position generates substantial switching costs for healthcare providers and patients alike. However, threats from emerging biopharmaceutical companies and the potential for generic competition, especially as patents expire, could challenge Gilead’s market dominance over the next 5-10 years.

Growth Engine

Future revenue growth for Gilead is expected to be driven by its strong portfolio in HIV treatments, including Biktarvy and Descovy, alongside innovative oncology therapies such as Yescarta and Trodelvy. The total addressable market (TAM) for HIV alone is projected to exceed $25 billion by 2027, fueled by increasing global awareness and access to therapies. Additionally, Gilead's strategic partnerships and collaborations with biotech firms enhance its pipeline for new product development, positioning the company to capture additional market share in both existing and emerging therapeutic areas.